Evercore ISI analyst Vijay Kumar raised the firm’s price target on Thermo Fisher (TMO) to $650 from $610 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target raised to $700 from $650 at BofA
- Thermo Fisher price target raised to $675 from $635 at Wells Fargo
- PayPal downgraded, Roku upgraded: Wall Street’s top analyst calls
- Thermo Fisher upgraded to Buy from Neutral at Citi
- Synopsys upgraded, Warner Bros. downgraded: Wall Street’s top analyst calls